US › Healthcare

Puma Biotechnology Inc (PBYI)

US · Healthcare · Biotechnology

$7.80+1.43%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$44.8M
Revenue YoY
-2.6%
Net profit
$-3.8M
Profit YoY
-226.2%
EPS
$-0.04
EPS estimate
$-0.13
Net margin
-8.4%

EPS came in at -0.04 against a street estimate of -0.13 — a beat of 69.2%.

Key statistics

Market cap
$403.6M
P/E
16.5
Forward P/E
3.5
P/B
3.14
Book value
$2.52
EPS (TTM)
$0.48
52-week high
$8.75
52-week low
$3.04
50-day MA
$7.68
200-day MA
$6.59
Beta
1.19

Analyst view

Analysts rate Puma Biotechnology Inc a hold (0 buy, 1 hold, 0 sell out of 1) with an average price target of $5.00.

Shareholding

Insiders
15.49%
Institutions
74.88%

Largest institutional holders

FundStake
BlackRock Inc7.07%
Acadian Asset Management LLC4.01%
Renaissance Technologies Corp3.82%
American Century Companies Inc3.77%
Vanguard Capital Management, LLC3.57%
Vanguard Portfolio Management, LLC3.41%
Millennium Management LLC2.90%
Dimensional Fund Advisors, Inc.2.82%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Puma Biotechnology Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.